Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC).
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Suresh Senan, Anthony M. Brade, Luhua Wang, Johan F. Vansteenkiste, Shaker R. Dakhil, Bonne Biesma, Maite Martinez Aguillo, Joachim Aerts, Ramaswamy Govindan, Belén Rubio-Viqueira, Conrad R. Lewanski, David R. Gandara, Hak Choy, Tony Mok, Anwar Hossain, Neill Allan Iscoe, Joseph Treat, Andrew G. Koustenis, Nadia Chouaki, Everett E. Vokes
Institutions: Amsterdam UMC Location Vrije Universiteit Amsterdam, University of Toronto, Princess Margaret Cancer Centre, Chinese Academy of Medical Sciences & Peking Union Medical College, KU Leuven, Cancer Center of Kansas, Jeroen Bosch Ziekenhuis, Complejo Hospitalario de Navarra, Erasmus MC, Amphia Ziekenhuis, Washington University in St. Louis, Hospital Universitario Quirónsalud Madrid, Charing Cross Hospital, UC Davis Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Chinese University of Hong Kong, Eli Lilly (United States), Eli Lilly (Canada), University of Chicago
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2612009132